Skip to main content

Advertisement

Table 1 Clinical inputs into the model and sources of information

From: Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Rate RIS-LAI Source PP-LAI Source
Probabilities
Adherence 0.823 Olivares [26] 0.872 RIS rate adjusted via Mehnert [27]
Adherent, stable disease 0.763 Calculation [1 - (ER exacerbation rate + hospitalization rate)] 0.803 Calculation [1 - (ER exacerbation rate + hospitalization rate)]
Adherent, exacerbation requiring ER visit 0.071 Ratio of ER vists: hospitalizations Ascher-Svanum [28] 0.059 Ratio of ER vists: hospitalizations Ascher-Svanum [28]
Adherent, hospitalized 0.166 Olivares [29] 0.138 Gopal [14], Hough [13]
Non-adherent, stable 0.140 Kane [30] 0.148 Hough [13]
Non-adherent, exacerbation 0.274 Calculation [1 - (Stable rate + hospitalization rate)] 0.299 Calculation [1 - (Stable rate + hospitalization rate)]
Non-adherent, hospitalized 0.586 Assumption; PP rate adjusted based on calculations by Mehnert & Diels [27] 0.553 Morken [31]
Dosing
Maintenance dose 40.3 mg biweekly Fleischhacker [15], Kissling [32], Lee [33], Lindenmayer [34], Olivares [29] 69.3 mg monthly Gopal[14], Fleischhacker [15]
Dose after relapse 50 mg biweekly* Risperdal Consta® Approved Summary of Product Characteristics [10] maximum dose 84.9 mg monthly Gopal [35], Pandina [36], Hough [16], Nasrallah [37], Pandina [38]
Dose after discontinuation 50 mg biweekly* Risperdal Consta® Approved Summary of Product Characteristics [10] maximum dose 150 mg week 1, 100 mg week 2, then 84.9 mg every 4 weeks Xeplion® Product monograph [12], Hough [13]
Clozapine maintenance after failing both drugs 450 mg daily Simonsen[23], Wahlbeck [24]   
Clozapine maximum dose 750 mg daily Simonsen[23], Wahlbeck [24]   
  1. ER emergency room, PP-LAI paliperidone palmitate long-acting injection (Xeplion®); RIS-LAI risperidone microspheres long-acting injection (Risperdal Consta®)
  2. *A slightly higher average dose of 58.2 mg biweekly was used in clinical trials in patients with acute eacerbations of schizophrenia by Kane [5], Chue [35], and Eerdekens[36]; however, they used a dose of 75 mg mg in some patients, which is not commercially available and which exceeds the now-recommended maximum.